Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of [111In-DTPA-D-Phe]-Octreotide in Patients With Refractory Malignancies Expressing Somatostatin Receptors

NCT00002947 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT00002947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00002947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of [111In-DTPA-D-Phe]-Octreotide in Patients With Refractory Malignancies Expressing Somatostatin Receptors
Lead sponsor
Yale University
Phase
Phase 1
Overall status
Terminated
Start date
October 31, 1996
Completion date
August 31, 2004
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors, childhood langerhans cell histiocytosis, gastrointestinal carcinoid tumor, head and neck cancer, intraocular melanoma, islet cell tumor, kidney cancer, lung cancer, melanoma (skin), neoplastic syndrome, neuroendocrine carcinoma of the skin, pheochromocytoma